Literature DB >> 7991583

Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.

I Benhar1, E A Padlan, S H Jung, B Lee, I Pastan.   

Abstract

B3(Fv)-PE38 is a recombinant single-chain immunotoxin in which the Fv region of carcinoma-specific antibody B3 is fused to a truncated form of Pseudomonas exotoxin (PE). The efficacy of monoclonal antibody B3 and B3 immunotoxins in cancer therapy and diagnosis may be limited by the human anti-mouse response. Here we describe the humanization of the Fv of B3(Fv)-PE38 by "framework exchange." The variable domains of the heavy (VH) and light (VL) chains were aligned with their best human homologs to identify framework residues that differ. Initially, 11 framework residues in VH and six in VL were changed by site-specific mutagenesis to human residues and introduced simultaneously into a preassembled single-chain Fv expression cassette. Six VH and five VL residues that differ were not changed because they were buried, in the interdomain interface, or previously found to result in decreased affinity when mutated. This basic design resulted in some 20-fold loss of activity. Changing VL residues at the interdomain interfacial position 100 and at the buried position 104 to the human sequence increased the activity 8-fold. Changing VH residue at position 82b from the human sequence back to that of the mouse restored the activity 2- to 3-fold to the full binding and cytotoxic activity of the mouse sequence. Humanized B3(Fv)-PE38 lost immunogenic epitopes recognized by sera from monkeys that had been immunized with B3(Fv)-PE38.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7991583      PMCID: PMC45374          DOI: 10.1073/pnas.91.25.12051

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  30 in total

1.  Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A.

Authors:  Y Satow; G H Cohen; E A Padlan; D R Davies
Journal:  J Mol Biol       Date:  1986-08-20       Impact factor: 5.469

2.  A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties.

Authors:  E A Padlan
Journal:  Mol Immunol       Date:  1991 Apr-May       Impact factor: 4.407

3.  Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains).

Authors:  J Novotný; M Handschumacher; E Haber; R E Bruccoleri; W B Carlson; D W Fanning; J A Smith; G D Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

4.  Replacing the complementarity-determining regions in a human antibody with those from a mouse.

Authors:  P T Jones; P H Dear; J Foote; M S Neuberger; G Winter
Journal:  Nature       Date:  1986 May 29-Jun 4       Impact factor: 49.962

5.  Structure and activity of diphtheria toxin. I. Thiol-dependent dissociation of a fraction of toxin into enzymically active and inactive fragments.

Authors:  R J Collier; J Kandel
Journal:  J Biol Chem       Date:  1971-03-10       Impact factor: 5.157

6.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

7.  Early restriction of the human antibody repertoire.

Authors:  H W Schroeder; J L Hillson; R M Perlmutter
Journal:  Science       Date:  1987-11-06       Impact factor: 47.728

8.  Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes.

Authors:  F W Studier; B A Moffatt
Journal:  J Mol Biol       Date:  1986-05-05       Impact factor: 5.469

9.  Contribution of human V kappa II germ-line genes to light-chain diversity.

Authors:  H G Klobeck; A Solomon; H G Zachau
Journal:  Nature       Date:  1984 May 3-9       Impact factor: 49.962

10.  Reshaping human antibodies for therapy.

Authors:  L Riechmann; M Clark; H Waldmann; G Winter
Journal:  Nature       Date:  1988-03-24       Impact factor: 49.962

View more
  4 in total

Review 1.  Multifunctional and stimuli-sensitive pharmaceutical nanocarriers.

Authors:  Vladimir Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2008-10-17       Impact factor: 5.571

Review 2.  Immunogenicity of therapeutic recombinant immunotoxins.

Authors:  Ronit Mazor; Masanori Onda; Ira Pastan
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 10.983

Review 3.  Clinical targeting recombinant immunotoxins for cancer therapy.

Authors:  Meng Li; Zeng-Shan Liu; Xi-Lin Liu; Qi Hui; Shi-Ying Lu; Lin-Lin Qu; Yan-Song Li; Yu Zhou; Hong-Lin Ren; Pan Hu
Journal:  Onco Targets Ther       Date:  2017-07-20       Impact factor: 4.147

Review 4.  Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.

Authors:  Yehudit Grinberg; Itai Benhar
Journal:  Biomedicines       Date:  2017-06-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.